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Abstract Multifocal motor neuropathy (MMN) is a rare in-
flammatory neuropathy characterized by progressive, asym-
metric distal limb weakness and conduction block (CB). Clin-
ically MMN is a pure motor neuropathy, which as such can
mimic motor neuron disease. GM1-specific IgM antibodies
are present in the serum of approximately half of all MMN
patients, and are thought to play a key role in the immune
pathophysiology. Intravenous immunoglobulin (IVIg) treat-
ment has been shown to be effective in MMN in five random-
ized placebo-controlled trials. Despite long-term treatment
with intravenous immunoglobulin (IVIg), which is efficient
in the majority of patients, slowly progressive axonal degen-
eration and subsequent muscle weakness cannot be fully
prevented. In this review, we will discuss the current under-
standing of the immune pathogenesis underlying MMN and
how this may cause CB, available treatment strategies and
future therapeutic targets.
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Introduction
Multifocal motor neuropathy (MMN) is a rare immune-
mediated, pure motor neuropathy with a prevalence of at least
0.6 per 100,000 individuals [1]. The male:female ratio is 2.7:1
[1] and the mean age at onset is 40 years, with a range of 20–
70 years [1–3]. In contrast to other immune-mediated
polyneuropathies such as the Guillain-Barre syndrome
(GBS) or chron ic in f l ammatory demyel ina t ing
polyneuropathy (CIDP), onset of MMN does not occur in
childhood or old age.
MMN is characterized by slowly progressive, asymmetric
muscle weakness in distal limbs. The ulnar, median, radial and
tibial nerves are most often affected [1, 4]. Muscles may be
atrophic, and there is a striking lack of sensory symptoms.
Other clinical features include muscle cramps, fasciculations,
and an increase of weakness in cold conditions [4, 5]. For a
more comprehensive overview of the clinical characteristics
and diagnostic criteria we would like to refer to the review by
Vlam et al. [4].
Persistent conduction block (CB) is the electrophysiologi-
cal hallmark of the disease, and distinguishes MMN from
motor neuron disease (MND) [6–8]. In contrast to patients
with MND, MMN patients have a normal life expectancy and
respond well to treatment with intravenous immunoglobulin
(IVIg). However MMN does not necessarily follow a benign
disease course, and up to 20 % of patients report relatively
severe disability predominantly of the upper limbs.
The pathophysiology of MMN remains to be elucidated.
Pathological studies are relatively scarce and have yielded
conflicting results [9–12]. The presence of antibodies against
GM1 and the favourable response to IVIg treatment support
an immune mediated pathophysiology. MMN has a distinct
overlap in clinical features with acute motor axonal neuropa-
thy (AMAN), the pure motor axonal form of GBS, implying
an analogy in underlying disease mechanisms. This further
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argues in favour of an immune mediated disease
pathophysiology.
In this review, we will focus on the immune pathophysiol-
ogy ofMMN and onCB, and how this knowledgemay help to
develop novel therapeutic strategies.
Immune Pathophysiology of MMN
Anti-GM1 IgM Antibodies
The presence of anti-GM1 IgM antibodies has been docu-
mented in the earliest descriptions of MMN [13], and is,
together with the virtually universal response to IVIg, the most
important clue that MMN is a primarily inflammatory disor-
der. Prevalence studies on GM1 antibodies are complicated by
methodological differences and the lack of a gold standard to
measure the presence and titre of these antibodies [14]. In a
recent study we found anti-GM1 antibodies in serum of at
least 50 % of a large cohort of patients with MMN using a
very specific ELISA protocol [1]. With the exception of a
minor subset of patients with anti-GM2 and anti-GD1b IgM
antibodies, both shown to be cross-reactive with GM1 in
absorption studies, we were unable to corroborate previously
reported associations with other anti-ganglioside antibodies
[4]. It is not understood why there is a lack of anti-GM1
antibodies in almost half of MMN patients. First of all, this
could be due to methodological issues, where a low sensitivity
could hamper detection of antibodies [14]. Furthermore it
could be that some, or even all, MMN patients harbour anti-
bodies against other, as of yet unknown, antigens [15–17].
This will be discussed in more detail further on.
Anti-GM1 IgM antibodies probably belong to the natural
antibody repertoire that are secreted by a specific subset of
innate B cells. In patients with MMN it may well be that anti-
GM1 IgM antibodies are produced by a single or very few B-
cell clones as shown by their restricted immunoglobulin light
chain use (Cats et al., unpublished data) and the association of
MMN with IgM monoclonal gammopathy (Vlam et al., un-
published data). High titres of these antibodies are associated
with MMN and are rare in patients with lower motor neuron
disease or GBS [1, 14, 18]. The titres of anti-GM1 IgM
antibodies correlate with their complement-activating capacity
in vitro [19, 20] and with the severity of muscle weakness [1].
Assuming a pathogenic role of anti-GM1 IgM antibodies,
the selective involvement of motor axons is not fully under-
stood. The most straightforward hypothesis is that GM1 is
selectively expressed in motor nerves, implying an increased
vulnerability of motor axons to anti-ganglioside antibodies.
Experimental studies have addressed this issue, and one such
study found GM1 to be more abundant in the ventral roots
compared to dorsal roots [21], but this has not been corrobo-
rated in other studies [22, 23]. However, from these studies it
is also apparent that GM1 is, to some degree, also present in
unaffected nerves. For this reason, even if there would be a
difference in GM1 expression in nerves, this cannot be the
sole reason for motor neuron selectivity in MMN.
Other explanations include slight differences in the molec-
ular composition of gangliosides between motor and sensory
nerves [22, 24] or differences in the association with other
glycolipids or the density of these structures on the axolemma
of motor and sensory nerves [25–27]. Findings in AMAN
support differences in GM1 expression between sensory and
motor nerves. Furthermore, serum from AMAN patients con-
taining GD1a-specific IgG antibodies show preferential bind-
ing tomotor axons, despite a lack of quantitative differences in
GD1a ganglioside expression [22, 28]. Differences in the fatty
acid chain length of the ceramide portion of gangliosides [22]
or differences in cholesterol content in motor and sensory
axons could induce changes in the expression of specific
GM1 epitopes and thereby determine antibody-binding op-
portunities. Finally, it may be that anti-GM1 IgM antibodies
bind to bothmotor and sensory nerves, but that sensory nerves
are less vulnerable to damage due to differences in biophysical
properties. This is supported by the finding that slight changes
in vibration sense occur in patients with MMN with longer
disease duration [1].
Pathogenic Effects Mediated by Anti-GM1 Antibodies
Anti-GM1 IgM antibodies may trigger direct and complement
dependent damage to axons (see Fig. 1). Experimental models
of AMAN have illustrated that interaction of anti-ganglioside
antibody with complement is a crucial step in the pathogene-
sis. Complement-activating properties of anti-GM1 antibodies
were associated with the occurrence of weakness in the rabbit
model of AMAN [29]. Complement activation leads to struc-
tural alterations in the paranodal region and subsequent dis-
ruption of ion channel integrity [30] through activation of the
classic complement pathway that results in formation of mem-
brane attack complex (MAC). MAC is a porin that compro-
mises membrane integrity [30, 31], allowing uncontrolled ion
flux. This may eventually lead to calpain activation and sub-
sequent paralysis of the endocytic machinery of the cell and
disruption of sodium channels, allowing further binding of
antibodies to the axolemma [32]. Interestingly there is an
increased vulnerability to complement mediated injury of
distal nodes of Ranvier in motor axons compared to proximal
nodes [31], possibly explaining the distal dominant pattern of
weakness as observed in patients. The use of complement
inhibitors abrogates the anti-ganglioside antibody mediated
damage in animal models, providing more evidence for com-
plement dependent pathology [31, 33, 34]. Although in vitro
or animal models for MMN are not available, several studies
have shown that anti-GM1 IgM antibodies in sera from pa-
tients with MMN also activate the classic complement
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pathway, and that their complement-activating potential cor-
relates with antibody titres [19, 35] and weakness (Vlam et al.,
unpublished data). High innate activity of the classical com-
plement pathway and efficient activation of this pathway
correlates with both more severe axonal loss and weakness
in MMN patients (Vlam et al., unpublished data).
Blood Nerve Barrier Disruption
The peripheral nerves are protected by the blood-nerve barrier
(BNB) from inflammatory cells and antibodies. The large
molecular size of anti-GM1 IgM antibodies (900 kD) [36]
suggests that BNB disruption plays an important role inMMN
pathogenesis. Rare pathological studies have reported
perivascular lymphocytic infiltration in the endoneurial
microvessels of the BNB [9–12]. The presence of circulating
cytokines, such as VEGF, TNF-α, and IL-1β, appears to be
linked to dysfunction of the BNB in MMN patients [37]. A
recent study using an in vitro BNB model, consisting of
conditionally immortalised human BNB-derived endothelial
cells, has suggested that VEGF is the main effector molecule
linked to the pathogenesis of the BNB breakdown [38]. Al-
though serum concentrations of VEGF did not differ between
MMN patients and healthy controls, the addition of a
neutralising anti-VEGF antibody to the MMN sera resulted
in restoration of BNB function [38]. VEGF secretion by
endothelial cells was increased after incubation with MMN
sera, suggesting the effect of VEGF occurred via an autocrine
mechanism.
Pre-synaptic Motor Nerve Terminal Uptake
In addition to gangliosides in the paranodal region of motor
neurons, several studies suggest that auto-antibodies may also
target antigens in the presynaptic membrane of the neuromus-
cular junction (NMJ). Gangliosides at this site are likely
targets since their density at the synaptic membrane is rela-
tively high [39], and there is no BNB to offer protection.
Gangliosides at the presynaptic membrane of the NMJ under-
go recycling through endosomal pathways [40].
Despite their physiological synaptic abundance, the role of
complex gangliosides at the NMJ is unclear. They seem
dispensable for transmitter release and more specifically elec-
trophysiological signal propagation at the neuromuscular
junction. This is supported by normal electrophysiological
properties in transgenic mice lacking all gangliosides except
for GM3 [41, 42]. Studies using in vitro incubation of mouse
hemidiaphragm preparations with anti-ganglioside antibodies
showed nerve terminal damage and electrophysiological in-
vestigations revealed block of signal transmission [43]. It must
be noted that this process was complement-dependent. The
relevance of this mouse-model for MMN pathogenesis is
unknown. A recent study by Fewou et al. [40] showed that
rapid internalisation of anti-ganglioside antibodies at the pre-
synaptic membrane prevented complement-mediated cytotox-
icity. This protective mechanism is not available at the nodes of
Ranvier and paranodal regions, and could thus explain why
dysfunction of these structures underlies MMN pathogenesis.
In contrast to the local (para)nodal neurotoxic effect, the effect
of antibody internalisation and retrograde transport is not fully
understood. Further studies are needed to determine the possi-
ble toxic effect of antibody uptake and retrograde transport [40].
Origin of Pathogenic Antibodies
The mechanisms of B cell activation leading to elevated anti-
GM1 IgM titres in MMN are yet to be established. Unlike
AMAN, associations with preceding microbial or viral infec-
tions leading to the production of cross-reactive anti-
ganglioside antibodies through molecular mimicry have not
been reported in MMN [44]; the slowly progressive, chronic
nature of MMN makes studying preceding infections more
challenging compared to the more acute disease course of for
example AMAN. Alternatively, monoclonal B-cell prolifera-
tion is suggested by an increased frequency of IgM monoclo-
nal gammopathy, which is seen more frequently in patients
compared to healthy controls (Vlam et al., unpublished data).
However there are no studies on the cellular content of bone
marrow of patients with MMN.
MMN lacks features of classic autoimmune disease, with a
lack of response to corticosteroid treatment and a male pre-
dominance. Nevertheless, we found a slightly increased fre-
quency of autoimmune disease in MMN patients as compared
to controls, suggesting shared pathogenic mechanisms [45].
The HLA-DRB1*15 haplotype was increased among Dutch
patients with MMN, similar to patients with multiple sclerosis
and female patients with chronic inflammatory demyelinating
polyneuropathy (CIDP) [30]. Since there is no evidence that
T-cells play a role in MMN pathogenesis, the association with
HLA-DRB1*15 may reflect an increased propensity for the
production of autoantibodies, as has been suggested for a
number of other disorders [46].
Anti-GM1 IgM Negative Cases: Antibodies Against Other
Antigens?
Approximately half of all patients with MMN lack elevated
titres of anti-GM1 IgM antibodies in enzyme-linked immuno-
sorbent assay (ELISA) [1, 14]. It is unknown whether these
patients have low titres of anti-GM1 IgM antibodies that are
undetectable with ELISA, or whether they have antibodies
against other, as of yet unidentified, antigens. The clinical
characteristics of patients with and without anti-GM1 antibod-
ies do not differ, and treatment response is seen in seropositive
as well as in seronegative patients [20, 47], althoughweakness
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and disability are somewhat more pronounced in seropositive
cases on a group level [1].
Antibodies against NS6S (a disulphated heparin disaccha-
ride) have been found in patients with chronic inflammatory
neuropathies, and possibly in MMN [48]. However, the rele-
vance of NS6S as an antigen inMMN pathogenesis remains to
be corroborated. Earlier studies have suggested that
heteromeric complexes including GM1 facilitate increased
binding of GM1-specific antibodies. Heteromeric complexes
are structurally distinct glycolipids that interact to form new
molecular shapes capable of enhancing recognition by anti-
bodies [49]. Although we did not find antibodies to combina-
tions of gangliosides in sera from patients with MMN [1, 49],

















Fig. 1 Schematic model of putative disease mechanisms in MMN. Anti-
GM1 IgM antibodies may trigger direct and complement dependent dam-
age to axons. In the normal physiological situation the node of Ranvier is
characterized by clusters of ion channels, held together by GM1 and other
lipids in so called lipid rafts (I). These voltage gated sodium and slow
voltage gated potassium channels, together with fast voltage gated potas-
sium channels in the paranodal region, maintain normal saltatory conduc-
tion. Paranodal myelin is attached to the axon by GM1. Activated B cells
(plasma cells) produce the pentameric IgM antibodies that bind to GM1,
possibly to heteromeric complexes containing GM1, cholesterol and
galactocerebroside (not depicted in this figure) (II). The binding of these
anti-GM1 antibodies can lead to the first signs of demyelination and
possible dysfunction of the voltage gated sodium and slow voltage gated
potassium channels. Once there is binding of anti-GM1 antibodies to GM1
the classical complement pathway is activated, and deposition of comple-
ment factors such as membrane attack complex (MAC) can take place (III).
While focal demyelination continues, deposition of MAC may lead to
further disruption of the Schwann-cell-axolemma junctions, displacement
of ion-channel clustering and disturb membrane integrity at the (para)nodal
region. Loss of fast voltage gated potassium channels through severe
demyelination in the paranodal region can lead to leakage of potassium
and subsequent hyperpolarization. At the site of the neuromuscular junc-
tion (NMJ) (IV), anti-ganglioside antibodies are rapidly internalised after
binding, thus preventing the activation and deposition of complement
factors. It is as of yet unknown whether retrograde transportation into the
proximal part of the axon plays a role in the pathogenesis of MMN
J Clin Immunol (2014) 34 (Suppl 1):S112–S119 S115
strongly to a lipid mix of GM1, galactocerebroside and cho-
lesterol (GGC) [15]. These results have recently been
reproduced using both combinatorial glycoarray and ELISA,
suggesting that GM1/galactocerebroside complexes are spe-
cific antigens in MMN [16, 17].
The idea that heteromeric complexes, where accessory
lipids besides GM1, play a crucial role in the binding of
GM1-specific IgM antibodies and that possible interplay
between glycolipids in the bilipid membrane of axons can
substantially increase antibody binding is of great interest
in MMN. On a structural level there are three mechanisms
in which heteromeric complexes are thought to alter anti-
ganglioside antibody binding; through conformational mod-
ulation, steric hindrance and the generation of neo-epitopes
[49]. The formation of neo-epitopes by structural alteration
is yet to be proven at a molecular level. However, it has
been shown that cholesterol can induce changes in ligand
binding to glycolipids, by inducing a tilt in the glycolipid
receptor headgroup [50]. It is therefore not unthinkable that
galactocerebroside and cholesterol interact with GM1 in
such a way that its receptor affinity is significantly en-
hanced. On the one hand these recent studies provide hope
that the ELISA methodology and subsequent sensitivity can
be further increased, while on the other hand it offers new
insights into anti-ganglioside antibody induced pathogenesis.
Relationship Pathophysiology and Symptoms
How GM1-specific IgM antibody mediated immune patho-
physiology eventually leads to conduction block and muscle
weakness is not fully understood. Proposed mechanisms of
conduction block are threefold, namely through paranodal or
segmental demyelination, abnormal resting membrane poten-
tial, and finally disruption of the clustering of nodal sodium
channels and GM1 in lipid rafts [51, 52]. Experimental
models suggest that binding of anti-GM1 IgG [53] to GM1
in the axolemma causes blocking and disruption of sodium
channels. Sodium channel clustering is crucial for nerve con-
duction since it safeguards the safety factor for generating
action potentials and thus propagation of the signal.
Electrophysiological studies have shown signs of dysfunc-
tion at the nodes of Ranvier, with resting membrane changes
around sites of CB. Through paranodal disruption edema and
GM1-antibody complexes may preclude optimal functioning
of the electrogenic Na+/K+ ATPase to correct for continuous
Na+ influx resulting in permanent focal depolarization. Distal
of the CB, permanent hyperpolarization is seen probably due
to overactivation of Na+/K+ ATPase in order to remove the
Na-accumulation; since, per cycle, the pump removes 3 Na+
from the axon in exchange for 2 K+, increased activity results
in a more negative membrane potential. One hypothesis is
that at sensory nerves the density of Na+/K+ ATPase is higher
and their cumulative function can correct for the ion fluxes so
no conduction block is seen [51, 54–57]. The relatively rapid
response to IVIg treatment in all probability does not reflect
remyelination, and is more likely due to a decrease in persis-
tent Na+ current [58].
GM1 also plays a role in axo-glial integration and binding
of anti-GM1 IgM disrupts this resulting in demyelination and
finally to axonal degeneration.
Paresis of muscles innervated by affected nerves is the end
result. However, on nerve conduction studies more conduc-
tion abnormalities are seen than can be expected from a
clinical point of view [59]. It is not clear which mechanisms
can explain this discrepancy. One possibility is that findings
from nerve conduction studies precede clinic symptoms, but
long-term follow up studies to evaluate this are yet to be
performed.
Treatment
The only effective treatment options for MMN are intrave-
nous immunoglobulin (IVIg) and possibly subcutaneous im-
munoglobulin (SCIg) [3, 4, 60, 61]. The response rate to
IVIg is around 70–94 % [60, 62, 63]. Plasma exchange and
corticoids, effective in other immune mediated neuropathies
like CIDP, are not effective and can even lead to a clinical
deterioration. The use of high-dose cyclophosphamide, a
potent B cell suppressor, could reduce symptoms, however,
the risk of adverse events including neoplasms precludes
long-term usage [3, 4]. Add-on therapy with immunosup-
pressive drugs has been reported, but has not been assessed
in randomized trials with the exception of mycophenolate
mofetil, which did not alter clinical functioning or weekly
IVIg dosage [64].
IVIg exerts a range of immune modulatory mechanisms,
but it has not been established which are most relevant in
MMN. Since complement most probably plays an important
role in MMN pathogenesis, complement attenuation by IVIg
could be of great significance. IVIg may prevent C3 deposi-
tion in nerves and also reduce serum concentration of key
components of the classical complement pathway such as C1q
and C4 [19, 35], which are crucial in the pathogenesis of
immune mediated neuropathies [30].
Additional complement-modulating treatment strategies
may therefore be worth pursuing. Eculizumab, a monoclonal
antibody against C5 that prevents formation of membrane
attack complex (MAC), was safe in a small-scale pilot study,
but more detailed studies are needed to assess efficacy [65].
Nafamostat mesilate, a serine protease inhibitor with comple-
ment attenuating properties, was tested in animal models for
AMAN. It prevented complement deposition and
(subsequently) sodium channel disruption [66]. Up to this
point it has not been tested in patients with MMN.
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Another interesting approach is depletion of auto-reactive
B-cells. Beneficial effects of Rituximab, a monoclonal anti-
body against a B-cell specific antigen CD20, have been re-
ported in some studies, but most have not shown a sustainable
effect [67, 68]. Efficacy of this biological may be restricted to
patients with specific genotypes of the IgG Fc receptor
expressed on NK-cells, i.e. FcγRIIIA (FcγRIIIA-V/V1158),
as was suggested by a recent study in patients with a
polyneuropathy associated with IgM monoclonal
gammopathy [69].
Other Future Treatment Strategies
Tailor-made IVIg therapy for patients with MMN may be
another approach to improve treatment efficacy. Initial treat-
ment with IVIg typically consists of a dose of 2 g per kg
bodyweight in a 2 to 5 day course. Maintenance treatment
of 0.4–1.0 g per kg bodyweight every 1 to 4 weeks is
required in most patients to maintain improved muscle
strength. Peak concentration of IgG is detected immediately
after infusion, and rises to a 4-fold of normal levels [70].
There are nevertheless large differences in IgG pharmaco-
kinetics between patients. In patients with GBS, lower peak
concentrations after IVIg administration were an indepen-
dent predictor of unfavourable outcome [71]. A recent
study of IgG pharmacokinetics in 23 MMN patients during
first IVIg administration showed a similar trend. Higher
IgG elevation on day 1 was associated with a response to
IVIG [20]. SCIg has been proposed as an alternative to
IVIg. A drawback is that currently SCIg treatment is only
possible using small volumes and that patients will have to
use multiple infusions at multiple sites. The use of recom-
binant hyaluronidase (rHuPH20) allows a 10–15-fold vol-
ume increase of subcutaneously delivered IgG and this may
be a useful addition for future therapy [72].
Besides immune modulatory therapies, improving con-
duction properties of nerves may be another approach. 3,4
Diaminopyridine is a broad-spectrum inhibitor of fast
voltage-activated K+ (Kv) channels and improved action
potential propagation in in vitro models of demyelination.
In previous studies, it had no significant change on clin-
ical outcome or on conduction blocks in small patient
groups with CIDP, MMN and GBS and this was con-
firmed in a double blind placebo controlled study [73, 74].
The duration of administration lasted only several days
and longer schedules may be worth considering in future
trials.
Concluding Remarks
MMN is a rare pure motor neuropathy characterized by pre-
dominantly distal, asymmetric limb weakness with CB as an
electrophysiological hallmark. Despite the fact that the
pathogenesis of MMN is yet to be fully understood, there
are clear signs suggesting an immune-mediated pathogen-
esis. A beneficial response to IVIg underlines this, as does
the presence of anti-GM1 IgM antibodies in more than
half of MMN patients. The origin of these antibodies
together with the mechanism how anti-GM1 IgM antibod-
ies exert their neurotoxic effect at a molecular level re-
mains unclear. However functional studies have shown
complement activating potential of patient sera harbouring
anti-GM1 IgM antibodies, and models of AMAN have
highlighted the importance of complement dependent pa-
thology. Future research will be required to determine the
exact binding epitope of anti-GM1 antibodies, and if
heteromeric complexes containing GM1 and other lipids
in any way influence the binding affinity of these or other
unknown antibodies. Regardless of the underlying molec-
ular mechanism, it is the phenomenon of persistent con-
duction block and ultimately axonal degeneration that
results in muscle weakness. To date the only available
treatment is IVIg, which is efficacious in most patients.
However long term disability remains a problem, as mus-
cle weakness is slowly progressive in the majority of
patients despite treatment. A tailor-made approach to
modify IVIg therapy seems to be the best way to improve
current outcome for MMN patients. Other modes of ther-
apy could be improving the conduction properties of
nerves or attenuating complement activation. Further
studies are necessary to unravel the exact underlying
disease mechanism and uncover novel therapeutic targets
for this chronic and potentially debilitating disorder.
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